Physician profile
Rakesh P Gupta
NPI 1922144302
$27,713.62
in general payments reported to CMS, 2019-2025
39 companies · $4,471 in 2025
The $4,471 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,314 · 2020: $2,381 · 2021: $3,553 · 2022: $3,287 · 2023: $6,654 · 2024: $4,055 · 2025: $4,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $1,357 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,707.27 |
| Travel and Lodging | $1,356.57 |
| Education | $115.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,410.08 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $2,551.54 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $2,351.56 | 2019-2025 | Rotapro, Watchman Flx, Accolade Sr |
| Atricure, INC. | $2,145.11 | 2021-2024 | |
| Pfizer INC. | $1,965.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,419.97 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $1,269.88 | 2020-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $1,238.81 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $1,092.98 | 2019-2025 | |
| Amgen INC. | $1,022.14 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $923.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Vascular, INC. | $850.55 | 2019-2020 | |
| Edwards Lifesciences Corporation | $806.53 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Shockwave Medical, INC | $759.74 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $745.30 | 2021-2025 | Nexletol |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $742.41 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $636.58 | 2021-2025 | |
| Scpharmaceuticals INC. | $473.56 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $456.25 | 2023-2025 | Opsumit, Uptravi |
| W. L. Gore & Associates, INC. | $381.40 | 2021-2022 | |
| Abbott Laboratories | $329.15 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cardiovascular Systems INC. | $308.71 | 2021 | |
| Biotronik INC. | $282.24 | 2020-2024 | Acticor 7 Vr-T Dx |
| Lexicon Pharmaceuticals, INC. | $274.00 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $263.49 | 2022-2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $239.56 | 2019 | |
| Inari Medical, INC. | $192.20 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kestra Medical Technology Services, INC. | $134.35 | 2022-2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $128.42 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $75.43 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $60.94 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $40.47 | 2019-2023 | Evkeeza |
| Heartflow, INC. | $24.84 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $23.17 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $21.43 | 2021 | |
| Lilly USA, LLC | $21.13 | 2025 | Zepbound, Mounjaro |
| Baxter Healthcare | $19.13 | 2023 | Hillrom - Connex Spot Monitor |
| Akcea Therapeutics, INC. | $16.88 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.